Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Open Label, Single Group, Phase 1/2a Clinical Study to Evaluate the Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC Derived From hESC Line in AIS-A Level of Sub-acute SCI(From 7 to 60 Days)

NCT04812431 is registered in ClinicalTrials.gov with S.Biomedics Co., Ltd. as lead sponsor.

NCT NCT04812431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04812431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Open Label, Single Group, Phase 1/2a Clinical Study to Evaluate the Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC Derived From hESC Line in AIS-A Level of Sub-acute SCI(From 7 to 60 Days)
Lead sponsor
S.Biomedics Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 23, 2021
Completion date
September 30, 2030
Enrollment
5 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

spinal cord injury at c4 level with complete lesion, spinal cord injury at c5-c7 level with complete lesion, spinal cord injury, acute